Interestingly, although the expression level of THRA has not been found to be changed in TSCC patients, our analysis, using TCGA database derived head and neck squamous cancer (HNSC) patients, found certain mutations located in the ligand-binding domain and zinc finger domain of THRA. These findings suggest that possible dysregulations of THRA in cancer may involve the changes of its DNA binding or ligand-receptor interaction abilities. Here, THRA is linked to cancer.